CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology

We developed a SARS-CoV-2 vaccine candidate (CoV-RBD121-NP) comprised of a tobacco mosaic virus-like nanoparticle conjugated to the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 fused to a human IgG1 Fc domain. CoV-RBD121-NP elicits strong antibody responses in C57BL/6 mice and is...

Descripción completa

Detalles Bibliográficos
Autores principales: DeMarco, Jennifer K., Royal, Joshua M., Severson, William E., Gabbard, Jon D., Hume, Steve, Morton, Josh, Swope, Kelsi, Simpson, Carrie A., Shepherd, John W., Bratcher, Barry, Palmer, Kenneth E., Pogue, Gregory P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618284/
https://www.ncbi.nlm.nih.gov/pubmed/34835277
http://dx.doi.org/10.3390/vaccines9111346

Ejemplares similares

Ejemplares similares